Literature DB >> 19364513

The role of positive flow cytometry crossmatch in late renal allograft loss.

Ralph J Graff1, Huiling Xiao, Mark A Schnitzler, Patrick Ercole, Harvey Solomon, Tracy Pessin, Krista L Lentine.   

Abstract

Many studies relating flow cytometery crossmatch (FCXM) results to kidney transplant outcomes have examined risk in the first 3 to 12 months. We used Organ Procurement and Transplant Network registry data for 66,594 kidney transplants from 1995 to 2007 to investigate associations of T-cell positive (T+) and T-cell negative/B-cell positive (T(-)B+) FCXM with graft failure risk early (years 0-1) and late (years >1-5) after transplant. Compared with transplants with T-cell negative/B-cell negative (T(-)B(-)) FCXM, living-donor transplants performed after T+ FCXM had significantly higher adjusted, relative risks of both early (adjusted hazards ratio [aHR] 1.71, p < 0.0001) and late (aHR 1.36, p = 0.017) graft loss. T(-)B+ FCXM was associated with approximately 40% higher relative risk of graft loss in the late period only. Patterns were similar for deceased-donor transplants. The risks of positive FCXM persist beyond the peritransplant period for years after transplant. Damage by memory effector cells may explain the long-term risks associated with positive FCXM.

Entities:  

Mesh:

Year:  2009        PMID: 19364513      PMCID: PMC2729244          DOI: 10.1016/j.humimm.2009.04.002

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk.

Authors:  Howard M Gebel; Robert A Bray; Peter Nickerson
Journal:  Am J Transplant       Date:  2003-12       Impact factor: 8.086

2.  Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival.

Authors:  Krista L Lentine; Ralph J Graff; Huiling Xiao; Kian A Modanlou; Paolo R Salvalaggio; Daniel C Brennan; Brett W Pinsky; Thomas E Burroughs; Mark A Schnitzler
Journal:  Clin Transpl       Date:  2008

3.  Planned preimmunization of renal allograft recipients.

Authors:  W T Newton; C B Anderson
Journal:  Surgery       Date:  1973-09       Impact factor: 3.982

4.  Significance of the positive crossmatch test in kidney transplantation.

Authors:  R Patel; P I Terasaki
Journal:  N Engl J Med       Date:  1969-04-03       Impact factor: 91.245

Review 5.  Immunological enhancement and inhibition of tumor growth: relationship to various immunological mechanisms.

Authors:  N Kaliss
Journal:  Fed Proc       Date:  1965 Sep-Oct

6.  Hyperacute and acute kidney graft rejection due to antibodies against B cells.

Authors:  J C Scornik; W M LeFor; J C Cicciarelli; M E Brunson; T Bogaard; R J Howard; J R Ackermann; R Mendez; D L Shires; W W Pfaff
Journal:  Transplantation       Date:  1992-07       Impact factor: 4.939

7.  The flow cytometric crossmatch and early renal transplant loss.

Authors:  R J Mahoney; K A Ault; S R Given; R J Adams; A C Breggia; P A Paris; G E Palomaki; S A Hitchcox; B W White; J Himmelfarb
Journal:  Transplantation       Date:  1990-03       Impact factor: 4.939

8.  Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

Authors:  Stanley C Jordan; Dolly Tyan; Don Stablein; Matthew McIntosh; Steve Rose; Ashley Vo; Mieko Toyoda; Connie Davis; Ron Shapiro; Deborah Adey; Dawn Milliner; Ralph Graff; Robert Steiner; Gaetano Ciancio; Shobah Sahney; Jimmy Light
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

9.  Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss.

Authors:  H S Eng; G Bennett; E Tsiopelas; M Lake; I Humphreys; S H Chang; P T H Coates; G R Russ
Journal:  Am J Transplant       Date:  2008-09-08       Impact factor: 8.086

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.